Spectrum Pharmaceuticals has entered a co-development and commercialization agreement with TopoTarget A/S for belinostat, a histone deacetylase (HDAC) inhibitor, a deal worth a potential $350 million plus royalties on any net sales. (BioWorld Today) Read More